Published
March 19, 2026
American medical innovation is a story of lives saved, diseases conquered, and futures restored. It’s about grandparents meeting their grandchildren, entrepreneurs launching second careers, and scientists making discoveries that shape the future.
A new groundbreaking study by economists at the University of Chicago, commissioned by the U.S. Chamber of Commerce, reveals American medical innovation has delivered $167 trillion in societal value based on their analysis of a 30-year horizon across four major medical diseases.
These moments are made possible by a system that rewards innovation and delivers hope to millions of Americans. But our nation’s leadership in life sciences is at risk. Policies like Most-Favored Nation (MFN) price controls on medicines threaten to derail the innovation engine that has delivered so much for patients, families, and our economy.
The Transformative Power of Medical Innovation
Consider these remarkable achievements:
- HIV: In 1995, an HIV diagnosis was a death sentence, with patients living an average of just two years. Today, thanks to groundbreaking treatments, HIV patients can live full lifespans, an average of 40 additional years.
- Heart Disease: Advances in heart disease treatments have prevented heart attacks, extended survival, and added critical years to patients’ lives during their prime working age.
- Breast Cancer: Over the past three decades, breast cancer survival rates have dramatically improved, with patients living seven more years on average.
- Obesity: Still in its early stages, innovation in obesity treatments is poised to add nearly a year of life for millions of Americans while reducing the chronic disease burden.
The human value of these gains cannot be overstated. More parents will see their children graduate, more teachers will inspire the next generation, and more Americans will live fuller, healthier lives. These moments are made possible by a system that fosters groundbreaking discoveries and ensures access to life-saving treatments.
The Economic Engine of Innovation
And if that’s not enough, medical innovation is also an economic powerhouse. Healthy workers are productive workers, and the ripple effects are profound. These gains translate to real people earning paychecks, supporting families, and driving American competitiveness over a 30-year horizon.
- HIV: Medical advancements have generated $1.94 trillion in productivity gains and have also contributed $330 billion in federal tax revenue.
- Heart Disease: Innovations in heart disease treatments have delivered $1.12 trillion worth of productivity gains and have added $103 billion in federal tax revenue.
- Breast Cancer: Breakthroughs in breast cancer treatments have resulted in $1.21 trillion in productivity gains, along with an additional $49 billion in federal tax revenue.
- Obesity: Emerging treatments for obesity are projected to generate productivity gains valued at $6.48 trillion and additional federal tax revenue of $1.53 trillion.
In addition to these productivity and tax gains, innovations with respect to these four diseases result in savings in health spending totaling $574 billion over a 30-year horizon.
Utilizing a Value of a Statistical Year of Life – a common tool used by government agencies when doing cost-benefit analysis to quantify the monetary value of each year of life gained or extended because of policy changes – we can also quantify the overall health value gain from these medical innovations, including:
- $22 trillion in health value gains from advancements in the treatment of HIV,
- $13.74 trillion in health value gains from better treatments for heart disease,
- $25.13 trillion in health value gains from advances in breast cancer treatment, and
- $94.44 trillion in health value gains from new treatments for obesity.
Collectively, the economic, tax, health spending, and health value gains from recent medical innovation in these four areas total $167.50 trillion over a 30-year horizon.
These gains ultimately cascade through our economy, fueling consumer spending, innovation, tax revenue, and stronger communities. This is the often-overlooked fiscal reality: medical innovation is an investment with extraordinary returns.
The Threat of MFN Pricing: A Step in the Wrong Direction
Despite these returns, policies like MFN pricing threaten to undermine the innovation ecosystem that has proven crucial for patients and our economy. MFN pricing would tie U.S. medicine prices to those set by foreign governments with very different healthcare systems and limited access to innovative treatments, ultimately shackling our healthcare system to those without our history of innovation and advancement. While the goal of reducing prescription costs is worthy, the approach is deeply flawed.
In reality, MFN pricing would potentially reduce U.S. life sciences research and development spending by 18.5% and cut clinical trial activity by up to 75%. This would delay the development of new treatments, shift investment to countries with more favorable policies, and rob Americans of potential medical breakthroughs.
The economic toll would be devastating. MFN pricing threatens up to 2.2 million jobs in the life sciences sector and its supply chain. These are high-skilled, high-paying jobs that support local communities and drive our national economy, ultimately weakening our economic security and diminishing our global competitiveness.
But the greatest cost would be borne by patients. MFN pricing would slow the development of new treatments, delay access to life-saving medicines, and ultimately harm those who need innovation the most. It’s a step in the wrong direction at a time when we should be doubling down on what works.
Protecting the Future of American Cures
The past 30 years have shown that for every dollar we’ve invested in treating these conditions, we’ve generated health value, productivity, and tax revenue that will compound for decades to come. But this success story is not guaranteed.
To ensure that the American system of medical breakthroughs continues, we must:
- Reject MFN Pricing: Policymakers must understand that importing foreign price controls would jeopardize the innovation ecosystem that has made the U.S. a global leader in life sciences.
- Embrace Market-Based Solutions: Instead of imposing price controls, we should focus on solutions that lower costs while preserving the incentives that drive innovation.
- Defend Intellectual Property Rights: Strong IP protections are essential to incentivize the risky and costly R&D that drives medical breakthroughs.
- Invest in R&D: Continued investment in biomedical research is critical to unlocking the next generation of treatments and cures.
The stakes are too high to ignore. The next 30 years of medical breakthroughs could be even better than the last, if we have the courage to defend the system that has delivered so much for patients, families, and our economy.
Let’s protect what works, improve what can be better, and always put patients first.
About the author
Brad Watts
Brad Watts is the Senior Vice President at the U.S. Chamber of Commerce's Global Innovation Policy Center (GIPC). He works with U.S. Chamber members to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
